Approval

Bio-Thera gets China's first golimumab biosimilar approval

China's drug regulator cleared Bio-Thera Solutions' golimumab biosimilar to treat rheumatoid arthritis plus ankylosing spondylitis, the first such copy approved in the country. The same molecule won European approval in February and US approval in May. It is the seventh product, and sixth biosimilar, the company has brought to the Chinese market.

Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call